SCHEMBL4048808

SCHEMBL4048808

COc1ccc(Nc2[nH]nc3c2Cc2cc(Cl)ccc2-3)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 2/20 0.48
PDGFRB P09619 9/20 0.47
HIF1A Q16665 1/20 0.45
EGFR P00533 2/20 0.44
CDK1 P06493 1/20 0.44
PDGFRA P16234 1/20 0.44
PRKCA P17252 1/20 0.44
CHEK1 O14757 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
ATM Q13315 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALPL P05186 1/20 0.40
CLK1 P49759 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4041173 0.88 PDGFRB (0.51) PLK1PDGFRBHIF1AEGFRCDK1
SCHEMBL4045873 0.87 PDGFRB (0.42) PLK1PDGFRBCHEK1ACHE
SCHEMBL4044835 0.86 PDGFRB (0.46) PLK1PDGFRBHIF1APDGFRACHEK1
SCHEMBL4047927 0.86 PDGFRB (0.55) PLK1PDGFRBHIF1ACHEK1MEN1
SCHEMBL4046071 0.86 CHEK1 (0.42) PLK1PDGFRBCHEK1
SCHEMBL4050596 0.84 ACHE (0.47) PLK1PDGFRBEGFRPRKCACHEK1
SCHEMBL4041524 0.84 PDGFRB (0.44) PDGFRBEGFRCDK1PDGFRAPRKCA
SCHEMBL4051452 0.84 PDGFRB (0.51) PDGFRBHIF1AEGFRPDGFRACHEK1
SCHEMBL3087060 0.84 CHEK1 (0.54) PDGFRBHIF1ACHEK1
SCHEMBL4045920 0.84 PDGFRB (0.65) PDGFRBHIF1AMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795440-B2 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHARMACEUTICA NV (BE) 2010-09-14 US disclosed
US-7795440-B2 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHARMACEUTICA NV (BE) 2010-09-14 US disclosed
EP-1506175-B1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-01 EP disclosed
US-20070142305-A1 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders HO CHIH Y 2007-06-21 US disclosed
US-20070142305-A1 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders HO CHIH Y 2007-06-21 US disclosed
US-7196110-B2 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHAMACEUTICA N.V. (BE) 2007-03-27 US disclosed
US-7196110-B2 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHAMACEUTICA N.V. (BE) 2007-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142305-A1 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders PDGFRA, PDGFRB, PDGFA PLK1 98/4885PDGFRB 2/4885HIF1A 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.